1. Home
  2. BMEA vs SFBC Comparison

BMEA vs SFBC Comparison

Compare BMEA & SFBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMEA
  • SFBC
  • Stock Information
  • Founded
  • BMEA 2017
  • SFBC 1953
  • Country
  • BMEA United States
  • SFBC United States
  • Employees
  • BMEA N/A
  • SFBC N/A
  • Industry
  • BMEA Biotechnology: Pharmaceutical Preparations
  • SFBC Savings Institutions
  • Sector
  • BMEA Health Care
  • SFBC Finance
  • Exchange
  • BMEA Nasdaq
  • SFBC Nasdaq
  • Market Cap
  • BMEA 125.0M
  • SFBC 114.0M
  • IPO Year
  • BMEA 2021
  • SFBC N/A
  • Fundamental
  • Price
  • BMEA $2.15
  • SFBC $46.43
  • Analyst Decision
  • BMEA Strong Buy
  • SFBC
  • Analyst Count
  • BMEA 8
  • SFBC 0
  • Target Price
  • BMEA $10.63
  • SFBC N/A
  • AVG Volume (30 Days)
  • BMEA 658.3K
  • SFBC 5.2K
  • Earning Date
  • BMEA 10-28-2025
  • SFBC 10-29-2025
  • Dividend Yield
  • BMEA N/A
  • SFBC 1.64%
  • EPS Growth
  • BMEA N/A
  • SFBC 59.31
  • EPS
  • BMEA N/A
  • SFBC 2.43
  • Revenue
  • BMEA N/A
  • SFBC $38,045,000.00
  • Revenue This Year
  • BMEA N/A
  • SFBC N/A
  • Revenue Next Year
  • BMEA N/A
  • SFBC N/A
  • P/E Ratio
  • BMEA N/A
  • SFBC $19.12
  • Revenue Growth
  • BMEA N/A
  • SFBC 8.26
  • 52 Week Low
  • BMEA $1.29
  • SFBC $44.00
  • 52 Week High
  • BMEA $13.07
  • SFBC $55.85
  • Technical
  • Relative Strength Index (RSI)
  • BMEA 61.18
  • SFBC 49.43
  • Support Level
  • BMEA $1.98
  • SFBC $45.70
  • Resistance Level
  • BMEA $2.18
  • SFBC $47.90
  • Average True Range (ATR)
  • BMEA 0.12
  • SFBC 0.66
  • MACD
  • BMEA 0.01
  • SFBC -0.01
  • Stochastic Oscillator
  • BMEA 75.76
  • SFBC 44.94

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

About SFBC Sound Financial Bancorp Inc.

Sound Financial Bancorp Inc operates as the holding company for Sound Community Bank that provides traditional banking and other financial services for individuals and businesses. It attracts retail and commercial deposits from the public and invests those funds, along with borrowed funds, in loans secured by first and second mortgages on one-to-four-family residences including home equity loans and lines of credit, commercial and multifamily real estate, construction and land, consumer and commercial business loans. The bank also offers secured and unsecured consumer loan products, including manufactured home loans, floating home loans, automobile loans, boat loans, and recreational vehicle loans.

Share on Social Networks: